2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

2:30PM-4:00PM: Abstract Number: 3021

Frequency of Arthralgia, Seropositivity, and Seropositive Arthralgia and Their Association with Development of Rheumatoid Arthritis in a Cohort of Indigenous North Americans with or without a First Degree Relative with Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2998

Gut Microbiota Induce IGF-1 and Promote Bone Formation and Growth

Biology and Pathology of Bone and Joint

2:30PM-4:00PM: Abstract Number: 3027

Herpes Zoster in Patients with Moderate to Severe Rheumatoid Arthritis Treated with Baricitinib

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Small Molecules and Early Intervention

2:30PM-4:00PM: Abstract Number: 2996

High Fat Diet-Induced Osteoarthritis Progression Is Dependent on Toll-like Receptor 4

Biology and Pathology of Bone and Joint

2:30PM-4:00PM: Abstract Number: 3006

IFN-Gamma (IFNγ), IFNγ-Induced Chemokines and Other Biomarkers in Macrophage Activation Syndrome (MAS)

Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Juvenile Arthritis

2:30PM-4:00PM: Abstract Number: 3036

IL-22 Is Dysregulated in Psoriatic Arthritis and Acts to Limit IFN-γ Driven Inflammatory Chemokine Production

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology I

2:30PM-4:00PM: Abstract Number: 3045

Immunometabolism in ANCA-Associated Glomerulonephritis

Vasculitis III: Pathogenic Mechanisms

2:30PM-4:00PM: Abstract Number: 3003

Impact of Preoperative Opioid Use on Total Knee Arthroplasty Outcomes

Orthopedics, Low Back Pain and Rehabilitation

2:30PM-4:00PM: Abstract Number: 3010

Improvement of Spinal Inflammation Induced By Etanercept in Enthesitis Related Arthritis JIA-Patients. Data of the Reminder-Study

Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Juvenile Arthritis

2:30PM-4:00PM: Abstract Number: 2992

In Systemic Lupus Erythematosus with Antiphospholipid Antibodies, Hypocomplementemia Associates with Thrombosis

2016 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

2:30PM-4:00PM: Abstract Number: 3046

Inflammatory Pathways As Shared Molecular Targets Across ANCA-Associated Vasculitis and Nephrotic Syndrome

Vasculitis III: Pathogenic Mechanisms

2:30PM-4:00PM: Abstract Number: 3051

Is Frailty a Relevant Concept in Systemic Lupus Erythematosus (SLE)?

ARHP V: Epidemiology and Public Health

2:30PM-4:00PM: Abstract Number: 3023

Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Small Molecules and Early Intervention

2:30PM-4:00PM: Abstract Number: 3007

Long-Term Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results from a PHASE III Extension Study

Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Juvenile Arthritis

2:30PM-4:00PM: Abstract Number: 3011

Long-Term Outcomes after Disease Activity Guided Tapering of Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis: 3 Year Data of a Randomised Controlled Pragmatic Non Inferiority Strategy Study

Rheumatoid Arthritis – Clinical Aspects IV: Managing Patients in Remission

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].